The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 17, Issue 1, Pages 73-87
Publisher
Informa UK Limited
Online
2017-10-20
DOI
10.1080/14740338.2018.1390562
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition
- (2017) Teresa Amaral et al. EUROPEAN JOURNAL OF CANCER
- The mitogen-activated protein kinase pathway in melanoma part I – Activation and primary resistance mechanisms to BRAF inhibition
- (2017) Teresa Amaral et al. EUROPEAN JOURNAL OF CANCER
- Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients
- (2017) Adil Daud et al. Journal of Hematology & Oncology
- Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
- (2016) Sarah J. Welsh et al. EUROPEAN JOURNAL OF CANCER
- Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)
- (2016) Christopher J. Anker et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Learning from and engaging patients/families during the implementation of a new medical record system.
- (2016) Stephen Flaherty et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms
- (2016) Diptee Kulkarni et al. PHARMACOGENOMICS
- Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report
- (2016) Andrew J. Dooley et al. Targeted Oncology
- Radiosensitization by BRAF inhibitor therapy--mechanism and frequency of toxicity in melanoma patients
- (2015) M. Hecht et al. ANNALS OF ONCOLOGY
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade
- (2015) Ilaria Penna et al. Oncotarget
- Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma
- (2015) Giuliana Carlos et al. JAMA Dermatology
- Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial
- (2014) A. M. Menzies et al. ANNALS OF ONCOLOGY
- Cutis Verticis Gyrata in Association With Vemurafenib and Whole-Brain Radiotherapy
- (2014) James J. Harding et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations
- (2013) Giusy Gentilcore et al. BMC CANCER
- Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma
- (2013) A. Koop et al. BRITISH JOURNAL OF DERMATOLOGY
- Serious Skin Toxicity With the Combination of BRAF Inhibitors and Radiotherapy
- (2013) Imke Satzger et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity
- (2013) Natalia Rompoti et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
- (2013) Paolo A. Ascierto et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma
- (2013) Lisa Zimmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma
- (2013) Geoffrey T. Gibney et al. Nature Reviews Clinical Oncology
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma
- (2013) M. E. Lacouture et al. ONCOLOGIST
- Paradoxical oncogenesis: are all BRAF inhibitors equal?
- (2013) Alexander M. Menzies et al. Pigment Cell & Melanoma Research
- Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
- (2013) Alastair J. King et al. PLoS One
- Panniculitis With Arthralgia in Patients With Melanoma Treated With Selective BRAF Inhibitors and Its Management
- (2012) Lisa Zimmer ARCHIVES OF DERMATOLOGY
- Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing SelectiveBRAFInhibition
- (2012) Lisa Zimmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
- (2012) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study
- (2012) Emily Y. Chu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET ONCOLOGY
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Cutaneous toxicities of RAF inhibitors
- (2012) Rachael Anforth et al. LANCET ONCOLOGY
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials
- (2012) Christine M. Lovly et al. PLoS One
- RASMutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
- (2011) Patrick A. Oberholzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics
- (2010) Hui Cheng et al. CIRCULATION RESEARCH
- Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibition Results in Biphasic Alteration of Epidermal Homeostasis with Keratinocytic Apoptosis and Pigmentation Disorders
- (2010) K. Schad et al. CLINICAL CANCER RESEARCH
- Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
- (2010) Yevgeniy Balagula et al. INVESTIGATIONAL NEW DRUGS
- Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
- (2010) Jill C Rubinstein et al. Journal of Translational Medicine
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started